Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, available data suggest that MGF-driven restoration of redox homeostasis represents a central mechanistic axis of its antitumor activity, rather than merely a downstream branch of apoptosis (84,85).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [84]
In the citing paper
“Activation of oncogenes, aberrant metabolism, mitochondrial dysfunction, and loss of the tumor suppressor p53 can all promote increased ROS accumulation in cancer cells 69.”
From Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) · cites this paper as [69]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272 · cited 1×
“This is consistent with the high incidence of p53 mutation or loss of p53 function in over 50% of human cancer”
Background
Research works printed but not linked: 1
- Kim, G. J., Chandrasekaran, K. & Morgan, W. F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 21, 361–367 (2006). · DOI · Paper page
Cited by
Items 601–700 of 1,014
Zhang, P., Wang, Y., Lian, J., Shen, Q., Wang, C., Ma, B., Zhang, Y., Xu, T., Li, J., Shao, Y., et al. (2017) · Advanced Materials · doi:10.1002/adma.201702311 · Cited by 124
Thioether Phosphatidylcholine Liposomes: A Novel ROS-Responsive Platform for Drug Delivery
Du, Y., He, W., Xia, Q., Zhou, W., Yao, C., & Li, X. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b08901 · Cited by 125
Wang, L., Li, Y., Zhao, L., Qi, Z., Gou, J., Zhang, S., & Zhang, J. Z. (2020) · Nanoscale · doi:10.1039/d0nr05746k · Cited by 127
Safe and Targeted Sonodynamic Cancer Therapy Using Biocompatible Exosome-Based Nanosonosensitizers
Cao, T. G. N., Kang, J. H., You, J. Y., Kang, H. C., Rhee, W. J., Ko, Y. T., & Shim, M. S. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c22883 · Cited by 125
Qin, R., You, F.-M., Zhao, Q., Xie, X., Peng, C., Zhan, G., & Han, B. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01350-z · Cited by 139
“Compared to normal cells, cancer cells have higher levels of ROS due to increased metabolism and mitochondrial dysfunction [235].”
BackgroundSrivastava, N., Kollipara, R. K., Singh, D. K., Sudderth, J., Hu, Z., Nguyen, H. P., Wang, S., Humphries, C. G., Carstens, R. M., Huffman, K. E., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.003 · Cited by 143
“An altered redox state has long been observed in cancer cells, making transformed cells vulnerable to further increases in ROS levels and highly dependent on ROS detoxification systems (Cairns et al., 2011; Trachootham et al., 2009).”
Pharmacological targeting of ion channels for cancer therapy: In vivo evidences
Leanza, L., Managò, A., Zoratti, M., Gulbins, E., & Szabó, I. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.032 · Cited by 151
Gou, Y., Li, J., Fan, B., Xu, B., Zhou, M., & Yang, F. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.026 · Cited by 129
Application of Sodium Selenite in the Prevention and Treatment of Cancers
Kieliszek, M., Lipiński, B., & Błażejak, S. (2017) · Cells · doi:10.3390/cells6040039 · Cited by 125
“Furthermore, increased production of reactive oxygen species (ROS) may exhibits a high cytotoxic effect on cancer cells proliferation as compared to normal cells [36].”
BackgroundReactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications
Akter, S., Madhuvilakku, R., Kar, A. K., Nila, I. S., Liu, P., Inuzuka, H., Wei, W., & Hong, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02583-x · Cited by 172
Zhu, C., Hu, W., Wu, H., & Hu, X. (2014) · Scientific Reports · doi:10.1038/srep05029 · Cited by 126
Sridharan, D. M., Asaithamby, A., Bailey, S. M., Costes, S. V., Doetsch, P. W., Dynan, W. S., Kronenberg, A., Rithidech, K. N., Saha, J., Snijders, A. M., et al. (2015) · Radiation Research · doi:10.1667/rr13804.1 · Cited by 124
Hu, J., Lei, Q., Peng, M., Zheng, D., Chen, Y., & Zhang, X. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.010 · Cited by 129
Bekeschus, S., Wende, K., Hefny, M. M., Rödder, K., Jablonowski, H., Schmidt, A., von Woedtke, T., Weltmann, K., & Benedikt, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-03131-y · Cited by 127
Sun, Y., Qiao, Y., Liu, Y., Zhou, J., Wang, X., Zheng, H., Xu, Z., Zhang, J., Zhou, Y., Qian, L., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101977 · Cited by 131
Reactive oxygen species-responsive polymer drug delivery systems
Liu, J., Jia, B., Li, Z., & Li, W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1115603 · Cited by 157
“, 1998) and many diseases, such as cancer, neurodegenerative diseases, diabetes, and inflammation (Barnham et al., 2004; Fraisl et al., 2009; Trachootham et al., 2009; Schieber and Chandel, 2014; Shi et al., 2022).”
BackgroundZou, J., Jiang, C., Hu, Q., Jia, X., Wang, S., Wan, S., Mao, Y., Zhang, D., Zhang, P., Dai, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55658-0 · Cited by 143
Brodin, O., Eksborg, S., Wallenberg, M., Asker-Hagelberg, C., Larsen, E., Mohlkert, D., Lenneby-Helleday, C., Jacobsson, H., Linder, S., Misra, S., et al. (2015) · Nutrients · doi:10.3390/nu7064978 · Cited by 118
Oncogenic Alternative Splicing Switches: Role in Cancer Progression and Prospects for Therapy
Bonomi, S., Gallo, S., Catillo, M., Pignataro, D. S., Biamonti, G., & Ghigna, C. (2013) · International Journal of Cell Biology · doi:10.1155/2013/962038 · Cited by 135
“The synthesis of reduced glutathione (GSH), a reducing thiol peptide, protects cancer cells against ROS-mediated damage and confers resistance to anticancer therapies [118, 119].”
BackgroundLi, L., Zhang, Y., Zhang, L., Ge, S., Liu, H., Ren, N., Yan, M., & Yu, J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b00693 · Cited by 122
He, L., Wang, K., Zheng, Y., Cao, J., Zhang, M., Tan, C., Ji, L., & Mao, Z. (2018) · Dalton Transactions · doi:10.1039/c8dt00783g · Cited by 123
Wang, S., Yang, L., Cho, H.-Y., Dean Chueng, S.-T., Zhang, H., Zhang, Q., & Lee, K.-B. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119498 · Cited by 125
Wu, H., Wang, Y., Ying, M., Jin, C., Li, J., & Hu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00595-3 · Cited by 131
Emerging roles of PDGF-D signaling pathway in tumor development and progression
Wang, Z. P., Ahmad, A., Li, Y., Kong, D., Azmi, A. S., Banerjee, S., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.04.003 · Cited by 129
“DNA damage induced by ROS is sufficient to convert normal cells to malignant cells [36]; therefore, aberrant ROS signaling has profound consequence in inducing human malignancies.”
BackgroundDesai, A., Webb, B., & Gerson, S. L. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.10.040 · Cited by 120
“Efforts to inhibit scavengers such as glutathione are also underway [37].”
BackgroundWang, Z. P., Li, Y., & Sarkar, F. H. (2010) · Current Stem Cell Research & Therapy · doi:10.2174/157488810790442813 · Cited by 133
“TPA also shown to induce the expression of integrins and reduce the expression of E-cadherin in a PKC- and ROS-dependent manner [31].”
BackgroundInfluentialHace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes
Daugaard, M., Nitsch, R., Razaghi, B., McDonald, L., Jarrar, A., Torrino, S., Castillo-Lluva, S., Rotblat, B., Li, L., Malliri, A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3180 · Cited by 114
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 133
Zhou, D., Cao, X., Wang, Z., Hao, S., Hou, X., Qu, F., Du, G., Asiri, A. M., Zheng, C., & Sun, X. (2017) · Chemistry – A European Journal · doi:10.1002/chem.201700594 · Cited by 121
Oxidants, Antioxidants and Thiol Redox Switches in the Control of Regulated Cell Death Pathways
Benhar, M. (2020) · Antioxidants · doi:10.3390/antiox9040309 · Cited by 119
“In this context, it is widely appreciated that antitumor effects elicited by a range of treatment modalities (such as chemotherapy and radiotherapy) frequently involve oxidant-dependent mechanisms [17,18].”
BackgroundACTL6A protects gastric cancer cells against ferroptosis through induction of glutathione synthesis
Yang, Z., Zou, S., Zhang, Y., Zhang, J., Zhang, P., Xiao, L., Xie, Y., Meng, M., Feng, J., Kang, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39901-8 · Cited by 137
Policastro, L. L., Ibañez, I. L., Notcovich, C., Duran, H. A., & Podhajcer, O. L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4367 · Cited by 120
“As described, the threshold concept discriminates normal from malignant cells by their differential capabilities in maintaining redox homeostasis (304, 321).”
InfluentialRecent advances in nanomaterial-based augmented sonodynamic therapy of cancer
Um, W., E. K., P. K., Lee, J., Kim, C. H., You, D. G., & Park, J. H. (2021) · Chemical Communications · doi:10.1039/d0cc07750j · Cited by 120
Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development
Safe, S. H., Abbruzzese, J. L., Abdelrahim, M., & Hedrick, E. (2018) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0407 · Cited by 127
Glutathione system in animal model of solid tumors: From regulation to therapeutic target
Corso, C. R., & Acco, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.014 · Cited by 131
Zhang, P., Wang, C., Gao, K., Wang, D., Mao, J., An, J., Xu, C., Wu, D., Yu, H., Liu, J. O., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.063321 · Cited by 128
Hancock, C. N., Stockwin, L. H., Han, B., Divelbiss, R. D., Jun, J. H., Malhotra, S. V., Hollingshead, M. G., & Newton, D. L. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.10.696 · Cited by 127
“production and reliance on endogenous antioxidants [59].”
Ma, Z., Zhang, M., Jia, X., Bai, J., Ruan, Y., Wang, C., Sun, X., & Jiang, X. (2016) · Small · doi:10.1002/smll.201601681 · Cited by 119
Prodrug strategies for targeted therapy triggered by reactive oxygen species
Cadahía, J. P., Previtali, V., Troelsen, N. S., & Clausen, M. H. (2019) · MedChemComm · doi:10.1039/c9md00169g · Cited by 123
Shu, M., Tang, J., Chen, L., Zeng, Q., Li, C., Xiao, S., Jiang, Z., & Liu, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120574 · Cited by 118
Geng, B., Xu, S., Li, P., Li, X., Fang, F., Pan, D., & Shen, L. (2022) · Small · doi:10.1002/smll.202103528 · Cited by 119
Cao, T. G. N., Kang, J. H., Kim, W., Lim, J., Kang, S. J., You, J. Y., Hoang, Q. T., Kim, W. J., Rhee, W. J., Kim, C., et al. (2022) · Theranostics · doi:10.7150/thno.65516 · Cited by 125
“Oxidative stress-inducing anticancer therapies by increasing the concentration of reactive oxygen species (ROS) have recently emerged as an attractive option for efficient cancer treatment [1-3].”
BackgroundWalyEldeen, A. A., Sabet, S., El-Shorbagy, H. M., Abdelhamid, I. A., & Ibrahim, S. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110297 · Cited by 124
Updates of reactive oxygen species in melanoma etiology and progression
Liu-Smith, F., Dellinger, R., & Meyskens, F. L. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.04.007 · Cited by 115
“One consequence of this new balance is that a more robust antioxidant enzyme system exists in melanoma cells, which renders tumor cells extremely adaptive to challenges like ROSinducing chemotherapy drugs [90, 102].”
BackgroundCheng, X., Holenya, P., Can, S., Alborzinia, H., Rubbiani, R., Ott, I., & Wölfl, S. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-221 · Cited by 126
“There are strong evidences that adaptive mechanisms enable cancer cells to escape from oxidative damage [18,19] by means of overexpressing ROS scavengers including Thioredoxin (Trx) and/or Glutathione (Glu) and pro-survival proteins like Bcl-xl [20].”
BackgroundMoosavi, M. A., Sharifi, M., Ghafary, S. M., Mohammadalipour, Z., Khataee, A., Rahmati, M., Hajjaran, S., Łoś, M., Klonisch, T. C., & Ghavami, S. (2016) · Scientific Reports · doi:10.1038/srep34413 · Cited by 122
Yusupov, M., Wende, K., Kupsch, S., Neyts, E. C., Reuter, S., & Bogaerts, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-06412-8 · Cited by 118
Wang, S., Yu, G., Yang, W., Wang, Z., Jacobson, O., Tian, R., Deng, H., Lin, L., & Chen, X. (2021) · Advanced Science · doi:10.1002/advs.202002927 · Cited by 119
Reactive oxygen species-sensitive polymeric nanocarriers for synergistic cancer therapy
Cao, Z., Li, D., Wang, J., & Yang, X. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.023 · Cited by 126
Rutin (Bioflavonoid) as Cell Signaling Pathway Modulator: Prospects in Treatment and Chemoprevention
Pandey, P., Khan, F., Qari, H. A., & Oves, M. (2021) · Pharmaceuticals · doi:10.3390/ph14111069 · Cited by 140
Abdellatif, K. R. A., & Bakr, R. B. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02656-8 · Cited by 119
“Unfortunately, the conventional chemotherapy did not differentiate between the normal human cells and affected cells, causing many drawbacks [17, 18].”
BackgroundCurcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells
Cai, W., Zhang, B., Duan, D., Wu, J., & Fang, J. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.05.012 · Cited by 122
“One of many theories in cancer therapy is using ROS or oxidative stress-causing agents to kill cancer cells because it seems that cancer cells are more sensitive to ROS than normal cells (Raj et al., 2011; Trachootham et al., 2009).”
BackgroundRajesh, K., Krishnamoorthy, J., Kazimierczak, U., Tenkerian, C., Papadakis, A. I., Wang, S., Huang, S., & Koromilas, A. E. (2015) · Cell Death and Disease · doi:10.1038/cddis.2014.554 · Cited by 137
“Specifically, treatment with pro-oxidant drugs is considered an efficient strategy to kill cancer cells that exhibit increased tolerance to ROS.32,64,65 Because the PI3K-Akt pathway is upregulated in the majority of human cancers, exploiting the pro-death effects of Akt is considered to be an effective strategy in tum…”
BackgroundMethodResultInfluentialTheranostic nanosystems for targeted cancer therapy
Kang, H., Hu, S., Cho, M. H., Hong, S. H., Choi, Y., & Choi, H. S. (2018) · Nano Today · doi:10.1016/j.nantod.2018.11.001 · Cited by 118
Copper in cancer: from limiting nutrient to therapeutic target
Tang, X., Yan, Z., Miao, Y., Ha, W., Li, Z., Yang, L., & Mi, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1209156 · Cited by 133
Fatfat, M., Merhi, R. A., Rahal, O. N., Stoyanovsky, D. A., Zaki, A. M., Haidar, H., Kagan, V. E., Gali‐Muhtasib, H. U., & Machaca, K. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-527 · Cited by 128
Xiao, C., Ding, J., Ma, L., Yang, C., Zhuang, X., & Chen, X. (2014) · Polymer Chemistry · doi:10.1039/c4py01156b · Cited by 115
Multifunctional Polymeric Micelles with Amplified Fenton Reaction for Tumor Ablation
Wang, Y., Yin, W., Ke, W., Chen, W., He, C., & Ge, Z. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.7b01777 · Cited by 118
Zhang, C., Zheng, D., Li, C., Zou, M., Yu, W., Liu, M., Peng, S., Zhong, Z., & Zhang, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119472 · Cited by 117
Class I HDAC inhibitors enhance YB‐1 acetylation and oxidative stress to block sarcoma metastasis
El-Naggar, A. M., Somasekharan, S. P., Wang, Y., Cheng, H., Negri, G. L., Pan, M., Wang, X. Q., Delaidelli, A., Rafn, B., Cran, J., et al. (2019) · EMBO Reports · doi:10.15252/embr.201948375 · Cited by 118
“Links between ROS and cancer progression are well documented [64].”
Batinic-Haberle, I., Spasojevic, I., Tse, H. M., Tovmasyan, A., Rajic, Z., St. Clair, D. K., Vujaskovic, Z., Dewhirst, M. W., & Piganelli, J. D. (2012) · Amino Acids · doi:10.1007/s00726-010-0603-6 · Cited by 114
“…status, i.e. the balance between the endogenous antioxidant systems and reactive oxygen (ROS) and nitrogen (RNS) species, on cell function (Halliwell and Gutteridge 2007; Jones 2008; Trachootham et al. 2009; McCord 2000) has been accompanied by the need to restore it under pathological conditions.”
Tsuchihashi, K., Okazaki, S., Ohmura, M., Ishikawa, M., Sampetrean, O., Onishi, N., Wakimoto, H., Yoshikawa, M., Seishima, R., Iwasaki, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2121 · Cited by 127
Wu, H., Ying, M., & Hu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9746 · Cited by 108
“Clinical studies demonstrated that high level of lactate was a strong prognostic indicator of increased metastasis and poor overall survival [28, 29, 33, 34, 36-38].”
BackgroundHsu, H.-Y., Lin, T., Lu, M., Leng, P.-J., Tsao, S.-M., & Wu, Y. (2017) · Scientific Reports · doi:10.1038/srep44990 · Cited by 114
Mitochondrial metabolism-mediated redox regulation in cancer progression
Boese, A. C., & Kang, S. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101870 · Cited by 119
Reactive Oxygen Species-Based Nanomaterials for Cancer Therapy
Li, Y., Yang, J., & Sun, X. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.650587 · Cited by 135
Chen, W., Balakrishnan, K., Kuang, Y., Han, Y., Fu, M., Gandhi, V. V., & Peng, X. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401349g · Cited by 115
Chen, S., Ren, Q., Zhang, J., Ye, Y., Zhang, Z., Xu, Y., Guo, M., Ji, H., Xu, C., Gu, C., et al. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12103 · Cited by 118
“The endogenous antioxidant enzymes such as SOD, CAT, and GPx play crucial roles in the elimination of ROS [40, 59].”
BackgroundKim, B., Kim, H. S., Jung, E., Lee, J., Tsang, B. K., Lim, J. M., & Song, Y. S. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22332 · Cited by 114
“increase of ROS can promote cell proliferation and differentiation while excessive amounts of ROS cause oxidative damage to cells [4].”
BackgroundWan, Z., Mao, H., Guo, M., Li, Y., Zhu, A., Yang, H., He, H., Shen, J., Zhou, L., Jiang, Z., et al. (2014) · Theranostics · doi:10.7150/thno.8171 · Cited by 112
“On the other hand, singlet oxygen is considered as a highly reactive oxygen species (ROS) in cells, which plays an important role in the damage of subcellular organelles [18].”
BackgroundYue, C., Yang, Y., Song, J., Alfranca, G., Zhang, C., Zhang, Q., Yin, T., Pan, F., de la Fuente, J. M., & Cui, D. (2017) · Nanoscale · doi:10.1039/c7nr02193c · Cited by 116
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy
Heske, C. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01514 · Cited by 125
“This is particularly true in cancer cells which generally have increased ROS production and require very tight control of ROS balance (111).”
BackgroundReactive Oxygen Species Responsive Polymers for Drug Delivery Systems
Gao, F., & Xiong, Z. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.649048 · Cited by 113
“The development of a ROS-responsive drug delivery system is very important and has excellent prospects for application in the biomedicine field (Trachootham et al., 2009; Song et al., 2014).”
BackgroundWei, Q., Jiang, H., Xiao, Z., Baker, A. R., Young, M. R., Veenstra, T. D., & Colburn, N. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013012108 · Cited by 117
“Cancer cells have an enhanced defense system characterized by intrinsically higher expression of antioxidant proteins, and ROS are more likely to function as mediators of intracellular signaling cascades that are critical for maintenance of tumor phenotypes (3).”
BackgroundOpposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine
Cheung, E. C., Lee, P., Ceteci, F., Nixon, C., Blyth, K., Sansom, O. J., & Vousden, K. H. (2016) · Genes & Development · doi:10.1101/gad.271130.115 · Cited by 108
“Previous work has suggested that signaling and damaging ROS may be generated through different mechanisms as well as in different cell compartments (Trachootham et al. 2009).”
BackgroundInfluentialJabłońska, E., Gromadzińska, J., Pepłońska, B., Fendler, W. M., Reszka, E., Król, M. B., Wieczorek, E., Bukowska, A., Grešner, P., Galicki, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1680-4 · Cited by 112
ROS and energy metabolism in cancer cells: alliance for fast growth
Kang, S. W., Lee, S., & Lee, E. K. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0550-6 · Cited by 123
“Based on the fact that the cancer cells produce more ROS than the normal cells, there have been many trials for the ROS-based cancer therapy (Trachootham et al. 2009).”
BackgroundChang, C.-W., Chen, Y., Chou, S.-H., Han, C., Chen, Y., Yang, C.-C., Huang, C., & Lo, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0626 · Cited by 117
“Both SOD2 and CAT are antioxidant enzymes, and are associated with regulation of cellular ROS and the acquired drug resistance in cancer (15, 17, 35).”
In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells
Dwivedi, A., Mazumder, A., Plessis, D., du Preez, J. L., Haynes, R. K., & du Plessis, J. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.07.010 · Cited by 112
Targeting STAT3 with silibinin to improve cancer therapeutics
Bosch‐Barrera, J., Queralt, B., & Menéndez, J. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.003 · Cited by 115
Beyond Photo: Xdynamic Therapies in Fighting Cancer
Wang, S., Tian, R., Zhang, X., Cheng, G., Yu, P., Chang, J. K., & Chen, X. S. (2021) · Advanced Materials · doi:10.1002/adma.202007488 · Cited by 113
Chen, H., He, W., & Guo, Z. (2014) · Chem. Commun. · doi:10.1039/c4cc03385j · Cited by 111
Role of Vitamin E in Counteracting Oxidative Stress in Poultry
Panda, A. K., & Cherian, G. (2013) · The Journal of Poultry Science · doi:10.2141/jpsa.0130134 · Cited by 111
“…their outer molecular orbit such as superoxide, nitric oxide and hydroxyl radicals, and non-radical ROS, which do not have unpaired electron(s) but are chemically reactive and can be converted to radical ROS such as hydrogen peroxide, ozone, peroxynitrate and hydroxide (Trachootham et al., 2009).”
BackgroundNano-Fenton Reactors as a New Class of Oxidative Stress Amplifying Anticancer Therapeutic Agents
Kwon, B., Han, E., Yang, W., Cho, W., Yoo, W., Hwang, J., Kwon, B., & Lee, D. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b12523 · Cited by 115
Liu, Q., Lv, H., Wen, Z., Ci, X., & Peng, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01518 · Cited by 116
“5 mg/kg), (4) LPS + ISL (30 mg/kg), and (5) LPS + dexamethasone (5 mg/kg).”
BackgroundTrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy
McLoughlin, M. R., Orlicky, D. J., Prigge, J. R., Krishna, P., Talago, E. A., Cavigli, I. R., Eriksson, S., Miller, C. G., Kundert, J. A., Sayin, V. I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903244116 · Cited by 108
“ROS and thus make the cells more susceptible to oxidative stressinduced cell death compared with noncancerous cells (45, 57).”
BackgroundMetabolic regulation of ferroptosis in the tumor microenvironment
Mbah, N. E., & Lyssiotis, C. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101617 · Cited by 122
de la Vega, L., Grishina, I., Moreno, R., Krüger, M., Braun, T. W., & Schmitz, M. L. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.03.003 · Cited by 119
New Findings on Breast Cancer Stem Cells: A Review
Bozorgi, A., Khazaei, M., & Khazaei, M. R. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.4.303 · Cited by 119
“Both normal and cancer cells establish an equilibrium between production and depletion of ROS using compounds such as catalase, glutathione peroxidase, superoxide dismutase, and thioredoxin [96].”
BackgroundCun, J., Pan, Y., Zhang, Z., Lu, Y., Li, J., Pan, Q., Gao, W., Luo, K., He, B., & Pu, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121687 · Cited by 111
Yin, M., Ren, X., Zhang, X., Luo, Y., Wang, G., Huang, K., Feng, S., Bao, X., Huang, K., He, X., et al. (2014) · Oncogene · doi:10.1038/onc.2013.597 · Cited by 112
Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy
Ghosh, J. C., Siegelin, M. D., Vaira, V., Faversani, A., Tavecchio, M., Chae, Y. C., Lisanti, S., Rampini, P., Giroda, M., Caino, M. C., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju502 · Cited by 108
“The idea of targeting mitochondrial integrity for cancer therapy (19) has recently gained attention (35), and regulators of Bcl-2 proteins (36), oxidative phosphorylation (37), and redox mechanisms (38) have progressed through (pre)clinical development.”
BackgroundAnticancer Effect of Thymol on AGS Human Gastric Carcinoma Cells
Kang, S.-H., Kim, Y.-S., Kim, E., Hwang, J.-W., Jeong, J.-H., Dong, X., Lee, J. W., Moon, S.-H., Jeon, B.-T., & Park, P. (2016) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1506.06073 · Cited by 109
Rosa canina Extracts Have Antiproliferative and Antioxidant Effects on Caco-2 Human Colon Cancer
Jiménez, S., Gascón, S., Luquin, A., Laguna, M., Ancin-Azpilicueta, C., & Rodríguez-Yoldi, M. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159136 · Cited by 107
“Thus, low-to-moderate levels of ROS are essential for cellular proliferation, differentiation, and survival [51].”
BackgroundDNA Nanostructures Carrying Stoichiometrically Definable Antibodies
Setyawati, M. I., Kutty, R. V., & Leong, D. T. (2016) · Small · doi:10.1002/smll.201601669 · Cited by 109
Attia, M., Essa, E. A., Zaki, R. M., & Elkordy, A. (2020) · Antioxidants · doi:10.3390/antiox9050359 · Cited by 115
The antitumor activity of the fungicide ciclopirox
Zhou, H., Shen, T., Luo, Y., Liu, L., Chen, W., Xu, B., Han, X., Pang, J., Rivera, C. A., & Huang, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25255 · Cited by 106
“CPX also inhibits the iron-containing enzymes, such as catalase and peroxidase,(11) which are critical for decomposition of hydrogen peroxide, one of the reactive oxygen species involved in oxidative stress.(28) Whether CPX functions as an anticancer agent through iron chelation remains to be determined.”
BackgroundMatrix metalloproteinases in health and disease: regulation by melatonin
Swarnakar, S., Paul, S., Singh, L. P., & Reiter, R. J. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00812.x · Cited by 112
“ROS regulate many signal transduction pathways by directly reacting with and modifying the structure of proteins, transcription factors, and genes to modulate their functions [157].”
BackgroundInfluentialChen, S.-J., Hoffman, N. E., Shanmughapriya, S., Bao, L., Keefer, K., Conrad, K., Merali, S., Takahashi, Y., Abraham, T., Hirschler-Laszkiewicz, I., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620922 · Cited by 104
Wu, X., Zhu, Y. T., Yan, H., Liu, B., Li, Y., Zhou, Q., & Xu, K. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-269 · Cited by 108
“ROS is involved in signalling cell growth and differentiation, regulating the activity of enzymes, mediating inflammation by stimulating cytokine production, and eliminating pathogens and foreign particles [ 43 ].”
Background
Metadata
- Authors
- Trachootham, D., Alexandre, J., & Huang, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Huang, Peng
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-05-29
- Volume
- 8
- Issue
- 7
- Pages
- 579-591
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972779889
- Cited by
- 5,452
- References
- 163
- Citations by year
- 2026: 322 · 2025: 332 · 2024: 340 · 2023: 372 · 2022: 421 · 2021: 462 · 2020: 444 · 2019: 454 · 2018: 393 · 2017: 404 · 2016: 341 · 2015: 289 · 2014: 282 · 2013: 204 · 2012: 158
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA085563, R01CA109041, CA109041, R01CA085563, R01CA100428, CA100428)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- reactive oxygen species, oxidative stress, redox modulation, cancer cells, drug resistance, antioxidant capacity, anticancer agents, genomic instability
- MeSH terms
- Adaptation, Physiological, Animals, Glutathione, Humans, Neoplasms, Oxidation-Reduction, Neoplastic Stem Cells, Reactive Oxygen Species, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.